Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Smith & Nephew plc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.18, while Smith & Nephew plc trades at $30.11 (market cap $12.64B). The key difference: Smith & Nephew plc pays a 2.57% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| JPIN | SNN | |
|---|---|---|
52-Week High | $76.96 | $38.70 |
52-Week Low | $63.14 | $28.73 |
Market Cap | — | $12.64B |
Sector | — | Health |
Enterprise Value | — | $15.41B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.11, down 0.5% on the day, with technical indicators showing a neutral to bearish bias. The ETF lacks disclosed fundamental ratios, and a dividend of $0.91 is scheduled for June 2026. Recent coverage highlights its smart beta approach to international equity exposure since its 2014 launch.
The outlook remains neutral amid mixed technical signals and absent fundamental data. Risks include reliance on international markets and valuation opacity. Investor sentiment is cautious without clear earnings metrics or analyst consensus, requiring due diligence on underlying holdings and strategy.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
